Is gnách go bhfásann siadaí neuroendocrine pancreatic (NETanna) go mall, agus déanann an tsaotharlann monatóireacht ar an meall le haghaidh comharthaí fáis trí thástálacha íomháithe. Is gnách go mbíonn comharthaí cosúil le buinneach nó fadhbanna hormónacha ag othair a bhfuil NET ag leathadh amach as an briseán. Is féidir iad a úsáid le haghaidh drugaí mar octreotide, lanreotide, diazoxide, agus inhibitors caidéil prótón, a d'fhéadfadh bac a chur ar fhás meall.
When the patient’s symptoms cannot be controlled or the scan shows signs of meall growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
If all feasible treatments no longer work, then consider participating in clinical trials to test new therapies. Participation in clinical trials is likely to benefit some patients.
